Anthony Krick Email & Phone Number

Yardley, Pa, Us

Yardley, Pa, Us

West Chester, Pennsylvania, Us

- Responsible for the short term (budget / forecast) and long term (strat plan / valuation) financial planning of the organization.- Provide decision support and analysis for the entire organization (Commercial, R&D, Supply Chain, and Corporate Areas) with a focus on new product launches, product profitability (full P&L responsibility), revenue forecasting, Gross to Net, Investment / Contracting Strategy, ROI, etc.- Responsible for financial modeling and evaluation of potential business development transactions (in-license and out-license) and financing transactions (debt and equity)- Provide support to the Investor Relations process by preparing the quarterly earnings releases and tracking analyst reports (revenue and EPS consensus, valuation methodology, etc.)- Responsible for all Accounting and SEC Reporting Activities

- Finance business partner for the entire organization (Commercial, R&D, Supply Chain, and Corporate areas) with full P&L responsibility- Areas of focus include revenue forecasting (units and gross to net), short term financial planning (budget, forecast updates), long term strategic planning and cash flow management- Accountable for providing decision support for two new product launches, improving product profitability, business restructurings, and various ad hoc financial analysis for the Commercial organization (ROI, pricing, contracting strategy, etc.)- Responsible for financial modeling and evaluation of potential business development transactions (buy and sell side) and financing transactions (structured debt and equity)- Led the annual long-term strategic business planning process, including the valuation of the enterprise as well as valuations for individual products under various scenarios- Provide support to the Investor Relations process by preparing the quarterly earnings releases and tracking analyst reports (revenue and EPS consensus, valuation methodology, etc.)

Brentford, Middlesex, Gb

- Finance business partner for the US Vaccines Business Unit (VBU) within the US Pharmaceuticals Commercial Organization- Accountable for maximizing financial results for the US Vaccines business, including full P&L responsibility (Gross Sales, Gross-to-Net, Net Sales, Cost Of Goods Sold, Operating Expenses) for 2 Vaccine Product Franchises with annual revenues of over $1B. - Responsible for driving the strategic business plan for the VBU, supporting strategy and decision making on a short term and long term basis- Areas of focus include decision support, financial analysis for new product launches (1 new product launch and 2 re-launches of newly acquired products), product supply and resourcing analysis, product pricing and performance management- Serve as finance interface with VBU Sales and Marketing leaders to advise on how to achieve commercial and financial targets efficiently, while balancing risks and opportunities

Brentford, Middlesex, Gb

- Serve as finance support for three R&D Platform organizations (Clinical, Regulatory, and Medical)- Responsible for all budgeting, forecasting, and analysis activities- In addition, responsible for providing finance partnering and decision support for projects and significant business evaluations, including: business restructurings, global regulatory labeling compliance project, scenarios for clinical trial design options, “go / no go” decisions on clinical site expansions or reductions, various scenario analyses for outsource vs. “insource” decisions, etc.

Malvern, Pa, Us

- Finance Partner to Executive VP, Chief Scientific Officer and R&D leadership team- Responsible for the short term and strategic financial management of the Branded Pharmaceuticals Research and Development organization, including budgeting, forecasting, business restructurings and reorganizations, pipeline prioritization exercises, historical cost analysis, cost savings analyses, scenario / option analyses, variance analyses, risks & opportunities analysis, etc. - Areas of focus included all phases of drug development from Discovery through Phase III as well as approval and post marketing support (Phase IV, Medical Affairs, Regulatory Affairs etc.)- Led the financial coordination of Portfolio Review process, including preparing risk adjusted expected net present value analyses and scenario analyses for review by Senior R&D, Commercial and Financial leadership- Designed, led, and completed core areas of financial due diligence for acquisition targets, with a focus on revenue recognition, cost structure, inventory, and alliance agreements for R&D pipeline assets

Malvern, Pa, Us

- Finance Partner to the R&D organization with responsibilities for budget, forecasting, analysis, month end close activities, and strategic decision support activities- Partnered with R&D Project Leaders to develop and implement driver-based models to capture and track clinical trial expenditures based on site activation, patient enrollment, and other drivers- Worked closely with Treasurer on the establishment of the Company’s first revolving credit facility.

Malvern, Pa, Us

- Responsible for all SEC filings including: 10-K, 10-Q, 8-K, and Proxy Statement- Performed technical accounting research and documented accounting treatment for the application of new or proposed accounting standards and new business transactions including acquisitions, licensing/collaborative arrangements, revenue recognition, fair value considerations, equity method investments, and commitments and contingencies- Responsible for performing impairment tests for goodwill and definite lived tangible and intangible assets- Managed the external audit process, including quarterly reviews and the year-end audit- Coordinated Management’s Assessment for SOX purposes

London, Gb

- Served a variety of clients (Global and Domestic; Public and Private) in the Life Sciences and Manufacturing industries- Directed fieldwork daily, informed Senior Managers and Partners of the engagement status, and managed a team of 7 Senior Auditors and 9 Staff Auditors- Coordinated financial audit and SOX 404 procedures among 14 EY audit teams on-site at various client subsidiaries in the U.S. and Europe- Significant areas of technical focus included: Revenue Recognition, Acquisition Accounting, Goodwill and Intangible Asset Impairment, Restructurings and Discontinued Ops, Licensing Arrangements, Environmental Liabilities, etc.- Reviewed SEC filings: 10-K, 10-Q, S-3, S-8- Extensive experience with SOX 404 testing procedures, control rationalizations, identification of compensating controls, etc. - Served as a leading instructor in new staff technical training